HPV vaccines may reduce a wide range of genital diseases

Feb 05, 2010

High-coverage human papillomavirus (HPV) vaccinations among adolescents and young women may result in a rapid reduction of genital warts, cervical cell abnormalities, and diagnostic and therapeutic procedures, researchers report in a new study published online February 5 in the Journal of the National Cancer Institute. Some of these genital abnormalities are precursors of cervical, vulvar, and vaginal cancers.

This study was undertaken to determine if the administration of the reduced the risk of cervical intraepithelial neoplasia (CIN), a precursor of ; external anogenital and vaginal lesions (or external genital lesions) of any grade severity; Pap test abnormalities; and procedures such as colposcopy and definitive therapy or excision of lesions.

Nubia Muñoz, M.D., of the National Institute of Cancer, Bogotá, Colombia, and colleagues studied 17,622 women aged 15󈞆 years who were enrolled in one of two randomized, placebo-controlled, efficacy trials for the HPV6/11/16/18 vaccine. All women underwent cervicovaginal sampling and Pap testing.

In the group representing uninfected women, vaccination was up to 100% effective in reducing the risk of HPV16/18-related high-grade cervical, vulvar, and vaginal lesions and the risk of HPV6/11-related . In the group representing the general population, vaccination reduced the risk of any lesion, genital warts, Pap abnormalities, and definitive therapy, irrespective of HPV type. The reduction in risk was statistically significant.

"Our results provide strong evidence to suggest that the ongoing HPV vaccination programs in adolescent girls and young women will result within a few years in a notable reduction of genital warts, cervical cytological abnormalities, and diagnostic
and therapeutic procedures related to precursor lesions in the cervix, vulva, and vagina," the authors write. "It is anticipated that these reductions will eventually translate into lower rates of cancer of the cervix, vulva, and vagina."

Explore further: New cancer drug target involving lipid chemical messengers

More information: jnci.oxfordjournals.org

add to favorites email to friend print save as pdf

Related Stories

The Medical Minute: Cervical cancer awareness

Sep 16, 2009

(PhysOrg.com) -- Science has sought the “cause” of cancer for decades, and in the case of cervical cancer, the cause has been found. The cervix is the opening to the womb that is situated at the upper end of the vagina. ...

HPV vaccine reduces abnormal pap test results

Mar 10, 2008

In testing GARDASIL reduced abnormal Pap test results by 43 percent compared to women not given the vaccine, according new research. The findings show the approved anti-HPV agent appears to prevent the development of cell ...

New HPV vaccine under study

Nov 19, 2007

A new vaccine against nine of the most harmful strains of human papillomavirus is under study at the Medical College of Georgia.

Study on government's controversial choice of HPV vaccine

Jul 18, 2008

The UK government may save up to £18.6 million a year by deciding to use the HPV vaccine Cervarix, given that it is equally effective as the more expensive Gardasil in preventing cervical abnormalities, according to a study ...

Recommended for you

User comments : 0